SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-378994"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-378994" > First-in-class posi...

First-in-class positron emission tomography tracer for the glucagon receptor

Velikyan, Irina, 1966- (författare)
Uppsala universitet,Radiologi,Uppsala Univ Hosp, PET Ctr, Ctr Med Imaging, Uppsala, Sweden
Haack, Torsten (författare)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Bossart, Martin (författare)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
visa fler...
Evers, Andreas (författare)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Laitinen, Iina (författare)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Larsen, Philip (författare)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Plettenburg, Oliver (författare)
German Res Ctr Environm Hlth GmbH, Inst Med Chem, Helmholtz Zentrum Munchen, Neuherberg, Germany; Leibniz Univ Hannover, Inst Organ Chem, Hannover, Germany
Johansson, Lars (författare)
Antaros Med AB, Uppsala Sci Pk, Uppsala, Sweden
Pierrou, Stefan (författare)
Antaros Med AB, Uppsala Sci Pk, Uppsala, Sweden
Wagner, Michael (författare)
Sanofi Aventis Deutschland GmbH, Ind Pk Hochst, Frankfurt, Germany
Eriksson, Olof (författare)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Antaros Med AB, Uppsala Sci Pk, Uppsala, Sweden
visa färre...
 (creator_code:org_t)
2019-02-15
2019
Engelska.
Ingår i: EJNMMI Research. - : Springer Science and Business Media LLC. - 2191-219X. ; 9
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The glucagon receptor (GCGR) is emerging as an important target in anti-diabetic therapy, especially as part of the pharmacology of dual glucagon-like peptide-1/glucagon (GLP-1/GCG) receptor agonists. However, currently, there are no suitable biomarkers that reliably demonstrate GCG receptor target engagement.Methods: Two potent GCG receptor peptide agonists, S01-GCG and S02-GCG, were labeled with positron emission tomography (PET) radionuclide gallium-68. The GCG receptor binding affinity and specificity of the resulting radiopharmaceuticals [68Ga]Ga-DO3A-S01-GCG and [68Ga]Ga-DO3A-S02-GCG were evaluated in HEK-293 cells overexpressing the human GCG receptor and on frozen hepatic sections from human, non-human primate, and rat. In in vivo biodistribution, binding specificity and dosimetry were assessed in rat.Results: [68Ga]Ga-DO3A-S01-GCG in particular demonstrated GCG receptor-mediated binding in cells and liver tissue with affinity in the nanomolar range required for imaging. [68Ga]Ga-DO3A-S01-GCG binding was not blocked by co-incubation of a GLP-1 agonist. In vivo binding in rat liver was GCG receptor specific with low non-specific binding throughout the body. Moreover, the extrapolated human effective doses, predicted from rat biodistribution data, allow for repeated PET imaging potentially also in combination with GLP-1R radiopharmaceuticals.Conclusion: [68Ga]Ga-DO3A-S01-GCG thus constitutes a first-in-class PET tracer targeting the GCG receptor, with suitable properties for clinical development. This tool has potential to provide direct quantitative evidence of GCG receptor occupancy in humans.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)

Nyckelord

Glucagon
GCG
GLP-1 receptor
Dual agonist
Type 2 diabetes

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy